share_log

Panbela Therapeutics | 8-K: Current report

Panbela Therapeutics | 8-K: Current report

Panbela Therapeutics | 8-K：重大事件
美股SEC公告 ·  07/30 17:02

Moomoo AI 已提取核心信息

On July 24, 2024, Panbela Therapeutics, Inc. and its subsidiary, Cancer Prevention Pharmaceuticals, Inc., entered into a Loan Agreement with USWM, LLC, securing a term loan of $1.5 million. The loan, evidenced by a Term Promissory Note, is due by the earlier of a Qualifying Financing, a Qualifying Transaction, or December 31, 2024. The loan bears interest and a premium, with a maximum Qualifying Transaction Payment capped at $1 million. The proceeds are designated for specific uses, including payment to a contract research organization and other working capital needs. The Loan Agreement includes standard covenants and events of default, and the company has pledged to complete a Qualifying Financing by the end of 2024 and a Qualifying Transaction by July 24, 2025. To secure the loan, Panbela Therapeutics and its subsidiary granted a first priority security interest in their rights in an Asset Purchase Agreement to the lender. The full texts of the Loan Agreement, Term Note, and Security Agreement were filed with the SEC and are incorporated by reference into this report.
On July 24, 2024, Panbela Therapeutics, Inc. and its subsidiary, Cancer Prevention Pharmaceuticals, Inc., entered into a Loan Agreement with USWM, LLC, securing a term loan of $1.5 million. The loan, evidenced by a Term Promissory Note, is due by the earlier of a Qualifying Financing, a Qualifying Transaction, or December 31, 2024. The loan bears interest and a premium, with a maximum Qualifying Transaction Payment capped at $1 million. The proceeds are designated for specific uses, including payment to a contract research organization and other working capital needs. The Loan Agreement includes standard covenants and events of default, and the company has pledged to complete a Qualifying Financing by the end of 2024 and a Qualifying Transaction by July 24, 2025. To secure the loan, Panbela Therapeutics and its subsidiary granted a first priority security interest in their rights in an Asset Purchase Agreement to the lender. The full texts of the Loan Agreement, Term Note, and Security Agreement were filed with the SEC and are incorporated by reference into this report.
2024年7月24日，Panbela Therapeutics和其子公司Cancer Prevention Pharmaceuticals与USWm，LLC签订了一份贷款协议，获得150万美元的定期贷款。该贷款由定期本票证明，应于合格融资、合格交易或2024年12月31日之前到期。该贷款带有利息和溢价，并将合格交易支付上限最高限制在100万美元以下。所得款项用于特定用途，包括向合同研究机构支付费用和其他运营资金需求。贷款协议包括标准契约和违约事件，公司已承诺在2024年底完成合格融资，并在2025年7月24日之前完成合格交易。为确保贷款，Panbela Therapeutics和其子公司授予该贷款人其在资产购买协议中的权利的第一优先安全利益。贷款协议、定期票据和安全协议的全部文本已提交给SEC，并被引用并纳入本报告。
2024年7月24日，Panbela Therapeutics和其子公司Cancer Prevention Pharmaceuticals与USWm，LLC签订了一份贷款协议，获得150万美元的定期贷款。该贷款由定期本票证明，应于合格融资、合格交易或2024年12月31日之前到期。该贷款带有利息和溢价，并将合格交易支付上限最高限制在100万美元以下。所得款项用于特定用途，包括向合同研究机构支付费用和其他运营资金需求。贷款协议包括标准契约和违约事件，公司已承诺在2024年底完成合格融资，并在2025年7月24日之前完成合格交易。为确保贷款，Panbela Therapeutics和其子公司授予该贷款人其在资产购买协议中的权利的第一优先安全利益。贷款协议、定期票据和安全协议的全部文本已提交给SEC，并被引用并纳入本报告。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间